WALTHAM, Mass. and BOULDER, Colo. — August 26, 2025 — Leads & Copy — Cogent Biosciences, Inc. (Nasdaq: COGT) will participate in a fireside chat at the Citi Biopharma Back to School Conference on Wednesday, September 3, 2025, at 9:00 a.m. ET, the company said today. A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
Cogent also announced that the Compensation Committee of Cogent’s Board of Directors approved the grants of “inducement” equity awards to two new employees under the company’s 2020 Inducement Plan with a grant date of August 25, 2025. The employees received, in the aggregate, nonqualified options to purchase 54,500 shares of Cogent common stock. Each option has a 10-year term and a four-year vesting schedule.
Cogent Biosciences is focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
KIT D816V is responsible for driving systemic mastocytosis. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST). The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2/3 inhibitor. The Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.
Cogent Biosciences is based in Waltham, MA and Boulder, CO.
Contact: Christi Waarich, Senior Director, Investor Relations, christi.waarich@cogentbio.com, 617-830-1653
Source: Cogent Biosciences, Inc.
